I'm LongbridgeAI, I can summarize articles.Incannex Healthcare has secured a U.S. patent for its IHL-42X obstructive sleep apnea therapy, with a baseline expiry of July 9, 2040. This acquisition strengthens the company's exclusivity strategy for the oral combination therapy, which holds FDA Fast Track designation and positive Phase II data. Concurrently, Incannex is preparing to initiate patient recruitment for the DReAMzz Phase 2 dose-optimization study.
- Incannex won a U.S. patent covering the IHL-42X composition and methods to treat obstructive sleep apnea. * Baseline patent expiry set for July 9, 2040; patent term extension under review pending potential FDA approval. * Move strengthens exclusivity strategy for IHL-42X, an oral combination therapy with FDA Fast Track designation and positive Phase II data. * Company is preparing to start patient recruitment for the DReAMzz Phase 2 dose-optimization study. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-071745), on June 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here